18F-FDG PET/CT双时相显像在胰腺良恶性病变鉴别诊断中的应用

摘要

Objective To assess the clinical value of dual-time point 18F-FDG PET imaging for differential diag-nosis between benign pancreatic mass and pancreaticcancer. Method Twenty-four patients with pancreatic cancer and 10 patients with benign pancreatic mass underwent dual-time 18F-FDG PET imaging. Prophase scans and delayed scans were administered 50-60 min and 120-150 min after the intravenous injection of 18F-FDG, respectively. The maximum standardized uptake value (SUV) and SUVvariation (ΔSUV) were calculated for the twotime points. Re-sult In pancreatic cancer group, SUVprophase= 4.63±2.09, SUVdelayed= 5.86±2.74, and ΔSUV =(24.76±15.58)%, with sig-nificant difference (t =7.94, P <0.01). While in benign pancreatic mass group,SUVprophase= 2.48±0.95, SUVdelayed= 2.81± 1.18, and ΔSUV =(12.66±20.97)%, with significant difference (t =2.67, P <0.05), and SUVdelayed in pancreatic cancer group was significantly higher than thati in benigh pancreatic mass group (t =2.25, P <0.05). Conclusion Compared with benign lesion, the elevatory extent of SUVdelayed for pancreatic malignant lesions ishigher, while it is lower in mu-cinous adenocarcinoma. As a convenient method, dual-time point18F-FDG PET imaging is recommended in clinical practice.%目的：评价双时相显像在胰腺良恶性鉴别诊断中的应用价值。方法对24例胰腺癌患者和10例胰腺良性病变患者进行18F-FDG PET双时相显像（早注射FDG后50～60 min行早期显像，注射后120～150 min行延迟显像），测定两次显像病灶的标准摄取值（standard uptake value，SUV），并计算SUV变化率（ΔSUV）。结果胰腺癌组SUV 早期显像=4.63±2.09，SUV 延迟显像=5.86±2.74，ΔSUV=（24.76±15.58）%，差异有显著性（t=7.94，P<0.01）。而胰腺良性病变SUV 早期显像=2.48±0.95，SUV 延迟显像=2.81±1.18，ΔSUV=（12.66±20.97）%，差异有显著性（t=2.67，P<0.05），且胰腺癌组SUV 延迟显像明显高于良性病变组（t=2.25，P<0.05）。结论胰腺恶性病变SUV 延迟显像升高的幅度高于良性病变，但黏液腺癌SUV 延迟显像升高的幅度低于良性病变，总体而言，双时相显像方法简便，在临床上具有一定的实用价值。